From: Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials
Name of intervention | Number | Cochrane review | ||
---|---|---|---|---|
Studies | Participants | |||
Added to specific antipsychotic | ||||
Olanzapine | Â | |||
  Antipsychotic | Chlorpromazine | 1 | 39 |  |
 | Sulpride | 2 | 114 |  |
Risperidone | Â | |||
  Antipsychotic | Quetiapine | 1 | 144 |  |
Chlorpromazine | Â | |||
  Movement disorder drugs | LDOPA | 1 | 8 |  |
Haloperidol | Â | Â | Â | Â |
  Serotonin 5-HT3 receptor antagonist | Ondansetron | 1 | 121 |  |
Added to unspecified antipsychotic | Â | Â | Â | Â |
  Amino Acids | Glycine | 3 | 50 | [27] |
 | Serine | 1 | 39 | [27] |
  Antidepressants | Citalopram | 1 | 18 |  |
 | Escitalopram | 1 | 30 |  |
 | Mianserin | 1 | 18 |  |
 | Sertraline | 1 | 77 |  |
  Anticonvulsants and mood stabilisers | Valproate | 2 | 140 | [23] |
 | Carbamazepine | 3 | 79 | [28] |
 | Topiramate | 2 | 86 |  |
 | Lamotrigine | 1 | 38 | [24] |
 | Lithium | 5 | 227 | [25] |
  Antimicrobials | D-Cycloserine | 2 | 35 | [27] |
 | Ketoconazole | 2 | 24 |  |
  Herbal | Ning Xin Tang | 1 | 60 |  |
 | Ginkgo Biloba | 1 | 82 |  |
 | Yi Gan San | 1 | 59 |  |
  Movement disorder drugs | Apomorphine | 1 | 18 |  |
 | Tetrabenazine | 1 | 41 |  |
  Opioid acting drugs | Methadone | 1 | 7 |  |
  Salt or ester of benzoic acid | Benzoate | 1 | 60 |  |
  Histamine H2 receptor antagonist | Famotidine | 1 | 30 |  |
  Oestrogen receptor antagonist | Tamoxifem | 1 | 26 |  |